TORL 4 500
Alternative Names: TORL-4-500Latest Information Update: 17 Jun 2024
At a glance
- Originator TORL Biotherapeutics
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from the preclinical trials in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research 2024 (AACR-2024) .
- 04 Dec 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV) (NCT06005740)
- 22 Aug 2023 TORL Biotherapeutics and Translational Research In Oncology plan a first-in-human phase I trial in Solid tumours, including Liver cancer (Late-stage disease, Monotherapy) in USA (IV), in October 2023 (NCT06005740),